CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Income Statement [Abstract]
Net revenues	$ 132,660	$ 92,062	$ 350,413	$ 252,084	$ 351,318
Cost of revenues	28,395	22,900	78,365	63,820	88,606
Gross profit	104,265	69,162	272,048	188,264	262,712
Operating costs and expenses:
Research, development and clinical trials	32,818	18,766	88,008	55,262	79,003
Sales and marketing	29,364	23,830	86,658	69,871	96,675
General and administrative	27,061	22,711	79,073	64,198	87,948
Total operating costs and expenses	89,243	65,307	253,739	189,331	263,626
Operating income (loss)	15,022	3,855	18,309	(1,067)	(914)
Financial expenses (income), net	3,983	2,555	9,032	6,165	7,910
Income (loss) before income tax	11,039	1,300	9,277	(7,232)	(8,824)
Income tax	1,755	(630)	(5,614)	4,258	(1,594)
Net income (loss)	$ 9,284	$ 1,930	$ 14,891	$ (11,490)	$ (7,230)
Basic net income (loss) per ordinary share (in usd per share)	$ 0.09	$ 0.02	$ 0.15	$ (0.12)	$ (0.07)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	101,234,306	98,485,519	100,601,427	96,551,041	97,237,549
Diluted net income (loss) per ordinary share (in usd per share)	$ 0.09	$ 0.02	$ 0.14	$ (0.12)	$ (0.07)
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	108,643,814	107,604,578	108,113,416	96,551,041	97,237,549